01. Overview
About
The stem cell administration protocol depends on the type of disease therapy and the area of the body being injected. It may involve intravenous (IV), intramuscular (IM), intracutaneous (IC), or intra-articular infusion of 300 million adult mesenchymal stem cells (MSCs) derived from autologous adipose and/or bone marrow cultured in a laboratory.
The stem cell injection takes approximately 2-3 hours; MSCs are manually injected by a dedicated medical team.
Method
The intravenous administration of stem cells is considered the safest. Our medical team administers MSCs via intravenous injection. An IV line is inserted into the forearm, and the cells are delivered manually over several minutes.
This method helps to increase the number of viable cells, leading to greater treatment efficacy. This procedure is non-invasive and there is no pain associated with the cell injection.
02. Validation
Viability Testing
Viability testing refers to tests that determine whether cells are alive or dead. These tests assess the health, integrity, and function of the cells. Our laboratory’s minimum benchmark for viability is 80% – but we typically achieve higher rates of around 97%.
Ensuring high cell viability is part of our commitment to offering quality care. This not only meets GMP standards and regulations but also ensures that low viability or improper handling does not hinder the efficacy of our treatment therapies.
Our automated cell counter allows us to measure and assess stem cells quickly, consistently, and repeatedly. With this advanced tool, we can determine live versus dead cells, total and viable cell concentrations, and even verify counts through integrated imaging.
Immune Privileged
Mesenchymal stem cells (MSCs) exhibit immune-evasive properties that make them suitable for transplantation without eliciting a negative immune reaction.
These properties are primarily due to the low expression of major histocompatibility complex (MHC) class I molecules and the absence of MHC class II molecules on their surface. This allows MSCs to evade recognition by CD4+ T lymphocytes and prevent T-cell activation.
In the case of allogeneic transplantation, MSCs do not transfer or spread their DNA to patients receiving MSC therapy. The transient survival of infused MSCs, the lack of genomic integration from engineered transgenes, and the paracrine mechanism of action indicate that horizontal DNA transfer does not occur.
Clinical Research
ASC collaborates with leading academic research centers, principal investigators, and the national stem cell committee to validate our meticulously designed therapeutic stem cell protocols.
These are verified through accessible, patient-funded clinical studies. In combination with our dedicated stem cell clinical research and in vivo data generation, clinical studies allow us to discover more ways stem cells can benefit human health and combat inflammation.
Our studies, conducted under protocols approved by the Indonesian Ministry of Health, not only offer a promising avenue for those suffering from various conditions but also advance our contributions to the progress in the field of Regenerative Medicine.
03. Efficacy Data
Results
Study results are quantified by measuring changes in unique inflammatory markers in conjunction with subjective data. Patient response depends on a wide variety of biological factors, but also on the patient’s behavior and lifestyle.
Patients who adhere to an active lifestyle, an anti-inflammatory diet, and limit the consumption of alcohol, cigarettes, and caffeine may see sustained results for 4+ years, depending on their condition.
On average, patients have reported few signs of regression up to 48 months after stem cell therapy, and patients rarely return to their pre-therapy state. Our team of doctors will follow up with patients every 3 months for 24 months post-treatment to collect post-treatment efficacy data.
